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Several epidemiological studies have shown that high
levels of melatonin, an indolic hormone secreted mainly by
the pineal gland, reduce the risks of developing cancer,
thus suggesting that melatonin triggers the activation
of tumor-suppressor pathways that lead to the prevention
of malignant transformation. This paper illustrates that
melatonin induces phosphorylation of p53 at Ser-15
inhibiting cell proliferation and preventing DNA damage
accumulation of both normal and transformed cells.
This activity requires p53 and promyelocytic leukemia
(PML) expression and efﬁcient phosphorylation of p53 at
Ser-15 residue. Melatonin-induced p53 phosphorylation at
Ser-15 residue does not require ataxia telangiectasia-
mutated activity, whereas it is severely impaired upon
chemical inhibition of p38 mitogen-activated protein
kinase activity. By and large, these ﬁndings imply that
the activation of the p53 tumor-suppressor pathway is a
critical mediator of melatonin and its anticancer effects.
Therefore, it provides molecular insights into increasing
observational evidence for the role that melatonin has in
cancer prevention.
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Introduction
Melatonin (N-acetyl-5-methoxytryptamine) is a mam-
mal pineal hormone that is secreted and subtly regulated
by a circadian pacemaker located in the central nervous
system. This regulation occurs at the hypothalamic level,
which receives dark/light signals from the retina.
Melatonin is mainly secreted at night and its synthesis
is controlled by a set of enzymes. These enzymes are
inhibited by the presence of sunlight and become more
active in the dark. It has been reported that a reduction
in melatonin concentration may be correlated with an
increase in cancer occurrence. In fact, a number of
epidemiological studies have not only shown that light
exposure during night-shift work suppresses melatonin
production but also that night work has been associated
with an increased cancer risk. Several studies have
evaluated the comparison of light exposure in night-shift
workers with those of day-shift workers and its
correlation with various types of cancers. To further
support this association, studies conducted in blind
women have reported an inverse relationship between
the incidence of breast cancer and the degree of
sightedness, with a 40% lower risk of breast cancer
(Kliukiene et al., 2001; Flynn-Evans et al., 2009). It is
worthy to note that blind women produce higher levels
of melatonin as their retina receives less light and
therefore their pineal gland is less induced to reduce
melatonin production. Two prospective control studies
nested in larger cohorts have been recently published
(Schernhammer et al., 2008, 2010). The ﬁrst study,
conducted within the Hormones and Diet in the
Etiology of Breast Cancer Risk (ORDET) cohort, tested
the concentration of a melatonin metabolite, 6-sulfatox-
ymelatonin (aMT6s) in 178 postmenopausal women
with incident breast cancer and in 710 matched controls
(Schernhammer et al., 2010). The second case–control
study was within the National Health Interview Survey
(NHIS) cohort (Schernhammer et al., 2008). Both
studies show a strong inverse association between breast
cancer and overnight urinary melatonin levels of
aMT6s. Overall, these ﬁndings may indicate that
melatonin’s anti-neoplastic actions are highly associated
with triggering tumor-suppressor pathways. It has
previously been reported that melatonin induces both
p53 and p21waf1 protein expressions presumably high-
lighting its oncostatic actions (Mediavilla et al., 1999).
The p53 tumor-suppressor gene is frequently mutated in
human tumors. In normal cells, p53 is present in low
concentrations, owing to continuous and rapid degrada-
tion through the ubiquitin–proteasome system (Haupt
et al., 1997; Kubbutat et al., 1997). In response to a
plethora of stressful conditions, most notably those that
may lead to genomic damage, p53 becomes activated
(Wang and Prives, 1995; Shieh et al., 1997). This is
reﬂected in an increase, at times quite sharp, in the
overall amounts of the p53 protein within the cell, as
well as in various post-translational modiﬁcations that
augment the biochemical properties of p53. In its
activated state, p53 can drive various cell-fated changes,
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ranging from a transient growth arrest all the way to
replicative senescence and apoptotic cell death (Unger
et al., 1999; Oren, 2003).
In this paper, we show that melatonin activates p53 by
promoting its accumulation and phosphorylation at
Ser15. This pairs with a p53-dependent reduction of cell
proliferation and the ability to form colonies. In fact,
this effect is severely impaired in cells in which the p53
gene expression is selectively knocked down. We also
demonstrate that melatonin prevents DNA damage
accumulation in both normal and transformed cells.
This effect requires p53, PML protein expression and
efﬁcient phosphorylation of p53 at Ser-15 residue. The
latter is phosphorylated by ataxia telangiectasia-
mutated (ATM) kinase in response to g-irradiation,
whereas p38 mitogen-activated protein kinase (MAPK)
leads to phosphorylation of p53 in Ser-15 in response to
ultraviolet irradiation (She et al., 2000). Interestingly,
melatonin-induced p53 phosphorylation does not
require ATM activity as it occurs in both ATMþ /þ
and ATM/ human ﬁbroblasts and upon caffeine-
mediated inhibition of ATM kinase activity. Conversely,
by using speciﬁc inhibitors (PD98059 and SB202190)
of p38 MAPK activity, p53 phosphorylation at Ser-15
is abolished. As a result, melatonin-induced prevention
of DNA damage is impaired. Overall, these ﬁndings
emphasize that activation of the p53 tumor-suppressor
pathway may be a critical mediator in melatonin’s
anticancer activity.
Results
Melatonin induces p53-dependent inhibition of cell
proliferation
To ascertain whether melatonin triggers the activation of
tumor-suppressor pathways, we sought to analyze the p53
response to melatonin treatment of different cancer cell
lines. We found that melatonin treatment (1mM) of MCF-
7 and HCT116 cells for the indicated time points induces
both p53 and p21 protein accumulation (Figures 1A and
b). We also observed that melatonin triggers
p53 phosphorylation at Ser-15 residue but not at Ser-9,
Ser-37 and Ser-46 (Figures 1a and b, Supplementary
Figure S1F and data not shown). This pairs with no
modulation of p53 mRNA levels (data not shown). In
addition, melatonin treatment slows cell proliferation
(Figure 1c) and impairs the ability to form colonies
(Figure 1d) of MCF-7 cells. Inhibition of cell growth also
occurred in human fetal ﬁbroblasts (HFF) normal
primary cells (Halvorsen et al., 1999) (Supplementary
Figure S1A). To understand whether melatonin’s effects
on cell growth are p53 dependent, we measured the
growth of cells and their ability to form colonies in
isogenic HCT116 (Figures 1e and f) and HCT116 p53/
(Figures 1g and h) colon cancer cell lines. Inhibition of
cell proliferation by melatonin is lost in HCT116 p53/
cells (Figures 1g and h). We tested whether cell
proliferation inhibition was due to perturbations in the
cell cycle. Melatonin treatment induced a transient G2
arrest in MCF-7 cells (Figure 1i) and a transient G1
arrest, with a decrease in the S phase, in HCT116
cells (Figure 1l). These changes occurred within a few
hours after melatonin addition and could not be detected
later (Supplementary Figures S1B and C). We also
asked whether melatonin caused either apoptosis or
senescence. On the basis of cell growth curves, we
performed annexin V staining on MCF-7 cells treated
with melatonin for 72h and on HCT116 cells at 48 h after
treatment (Supplementary Figure S1D). Neither
of the cell lines showed apoptosis after melatonin
treatment. In addition, we tested whether melatonin
triggered senescence by senescence-associated b-galacto-
side staining by using the same experimental setup. As a
positive control, we used WRN/ ﬁbroblasts, which
undergo spontaneous senescence (Faragher et al., 1993).
We did not observe any variation in the number of
senescent MCF-7 or HCT116 cells upon melatonin
treatment (Supplementary Figure S1E). We speculate
that a transient delay of the cell cycle induced within a few
hours from adding melatonin would result in a decrease
in cell number.
Melatonin reduces genetic alterations after exposure
to DNA-damaging agents
It has been previously shown that p53 phosphorylation
at Ser-15 is associated with DNA damage response.
This prompted us to investigate whether melatonin may
trigger its cancer prevention action by activating p53.
Thus, by preventing the accumulation of mutations in
response to DNA insults, active p53 maintains the
integrity of the genome. To this end, we used the
random ampliﬁed polymorphic DNA (RAPD) techni-
que that allows the rapid and easy detection of genome-
wide genetic alterations (Xian et al., 2005). First, we
analyzed whether continuous treatment (for 5 days) with
melatonin provokes DNA mutations in both MCF-7
and MCF-10A breast cell lines by PCR amplifying the
genomic DNA with seven different primers. No muta-
tions were observed in both cell lines upon melatonin
treatment (Figure 2a). To assess the genetic alterations
induced by DNA-damaging treatment, we treated MCF-
7 and MCF-10A breast cell lines with and without
sublethal doses of chemotherapeutic drugs for 10 days
both in the absence and in the presence of melatonin. As
shown in Figure 2b, treatment with the DNA-damaging
agent Cisplatin (CDDP, lane 2) led to a change in the
ampliﬁcation pattern, indicating a generation of muta-
tions. Cells co-treated with melatonin and CDDP (lane
3) did not show any changes (or very modest changes) in
the band pattern as compared with untreated cells (lane
1), thereby suggesting that melatonin prevents DNA
mutations (Figure 2b). Subsequently, we hypothesized
that melatonin may prevent mutations by inducing
DNA repair. To test this hypothesis, we investigated
whether melatonin could affect DNA fragmentation by
performing comet assays. We treated MCF-10A
(Figure 2c) and MCF-7 (Figure 2d) cells, ﬁrst with
melatonin for 4 h and then by adding an alkylating
agent (CDDP) or antimetabolite (FU) or a topoisome-
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Figure 1 Melatonin activates p53. (a, b) MCF-7 (panel a) and HCT116 (panel b) cells were treated with 1 mM melatonin for
the indicated time; cells were lysed and protein extracts underwent immunoblot with the indicated antibodies. (c, e and g) MCF-7
(panel c), HCT116 (panel e) and HCT116 p53/ (panel g) cells were grown for the indicated time in the absence and in the presence
of 1 mM melatonin; cells were counted and the cell number is shown on the graph. (d, f and h) MCF-7 (panel d), HCT116 (panel f) and
HCT116 p53/ (panel h) cells were seeded and grown for 15 days in the absence or presence of 1 mM melatonin; colonies were stained
with crystal violet and counted. Colony number is shown. (i–l) MCF-7 (panel i) and HCT116 (panel l) cells were treated with melatonin
for the indicated time and BrdU incorporation was performed. Cell-cycle distribution is shown.
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rase inhibitor (Doxo) for 22 h. In addition, we
performed gamma-irradiation (IR, 10Gg) and comet
assays 3 h after irradiation. Comet assays revealed that
melatonin does not induce DNA damage per se and
reduces the number of comets generated by chemother-
apy and radiotherapy (Figures 2c and d). Overall, these
ﬁndings show that melatonin prevents DNA damage by
promoting DNA repair.
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Figure 2 Melatonin prevents DNA mutations. (a) MCF-7 and MCF-10A cells were grown in the absence or in the presence of 1 mM
Mel for 5 days; genomic DNA was extracted and RAPD analysis was performed. (b) MCF-7 cells were kept in culture for 10 days
with the indicated chemotherapeutic agent in the absence or in the presence of melatonin. The presence of DNA mutations
was assessed by RAPD analysis. Numbers indicate lanes. (c) MCF-10A cells were treated with 1mM melatonin for 4 h and then the
indicated chemotherapeutic agents were added for 22 h. Cells underwent comet assay. (d) MCF-7 cells were treated as described in
panel c; g-irradiation (10Gg) was performed 4 h after melatonin addition and cells were allowed to repair DNA for 3 h after
irradiation. Sample pictures are shown in the right panel.
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We asked whether melatonin-induced DNA repair
may protect cancer cells against chemotherapeutic
treatment. Therefore, we performed clonogenic assays
pretreating cells with melatonin for 4 h and then adding
either doxorubicin (Doxo) or cisplatin (CDDP) for
22 h. Despite promoting DNA repair, the presence of
melatonin did not interfere nor impede with chemother-
apy in impairing colony formation (Supplementary
Figure S2). The same results were observed when testing
cell proliferation (Supplementary Figures S3A–D).
Melatonin reduces DNA fragmentation through p53
and PML proteins
Given that we observed a p53-dependant reduction of
cell proliferation by melatonin, we asked whether
reducing DNA fragmentation would rely on p53 as well.
To this end, we used both MCF-7, the p53 expression of
which was selectively silenced, and isogenic HCT116 and
HCT116 p53/ cells. Melatonin reduced DNA frag-
mentation both in control siRNA-transfected MCF-7
cells and in HCT116 wild-type cells (Figures 3a and c),
but failed to do so in both p53 siRNA-transfected MCF-
7 and isogenic HCT116 p53/ cells (Figures 3b and d).
These ﬁndings showed that p53 protein expression was
required to reduce DNA fragmentation upon melatonin
treatment. These ﬁndings are further supported by
experiments performed in p53þ /þ and p53/ mouse
embryo ﬁbroblasts (Lapi et al., 2008). Again, melatonin
failed to reduce DNA fragmentation in mouse embryo
ﬁbroblast p53/ (Figure 4b), whereas it efﬁciently did in
their wild-type counterparts (Figure 4a). Growing
evidence reports that p53 orchestrates DNA damage
response and DNA repair by interacting with diverse
cellular partners. Among them, PML is closely connected
to p53 being both a p53 transcriptional target gene and a
p53-interacting protein (Guo et al., 2000; Pearson and
Pelicci, 2001; Bernardi et al., 2004). Therefore, we
investigated the potential involvement of PML protein
in cellular responses to melatonin. First, we examined
PML protein levels upon melatonin treatment. We
observed that melatonin induced PML accumulation
(Figures 4c and d), similar to p53 (Figures 1A and b).
We then performed comet assays in PML/ mouse
embryo ﬁbroblast and found that PML deﬁciency
impaired melatonin’s capability to reduce DNA frag-
mentation (Figure 4e), suggesting that PML is required
for this process. To ascertain whether PML has a direct
role in melatonin-induced p53-dependent DNA repair,
we tested whether PML may be involved in
the phosphorylation of p53 after melatonin treatment.
We silenced PML and then treated cells with melatonin
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Figure 3 Melatonin inhibits DNA fragmentation in a p53-dependent manner. (a, b) MCF-7 cells were transfected with control
siRNA (panel a) or p53 siRNA (panel b) and treated as described in Figure 2c. (c, d) HCT116 wt (panel c) and p53-/- (panel d) cells
were treated as in panel a. Percentage of comets is shown.
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for 2 h. Our ﬁndings showed that PML knockdown
impaired phosphorylation of p53 induced by melatonin
(Figure 4f).
We also investigated whether melatonin could inﬂu-
ence the expression of other DNA damage-related
proteins that either cooperate with or regulate p53, such
as ATM and H2AX (Banin et al., 1998; Fernandez-
Capetillo et al., 2002; Nur et al., 2003; Shrivastav et al.,
2008). The latter becomes phosphorylated upon DNA
damage and acts as a sensing and repair molecule (Lukas
and Bartek, 2009). Upon treating MCF-7 and HCT116
cells with melatonin for the indicated time, we checked the
protein levels of H2AX phosphorylated in Ser-139
(gH2AX). Interestingly, we observed an increase in
gH2AX protein levels in both MCF-7 (Figure 4c) and
HCT116 cell lines (Figure 4d). We ascertained that
melatonin-induced H2AX phosphorylation was not
totally due to an increase in the total level of H2AX
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Figure 4 Melatonin inhibits DNA fragmentation in a PML-dependent manner. (a, b and e) MEF wt (panel a), p53/ (panel b) and
PML/ (panel e) underwent comet assay. Percentage of comets is shown. (c, d) MCF-7 (panel c) and HCT116 (panel d) cells were
treated with 1mM melatonin for the indicated time and protein extracts underwent immunoblot with the indicated antibodies.
(f) HCT116 cells were transfected with control siRNA and PML siRNA. Ninety-six hours after transfection, cells were treated with
melatonin for 2 h. Cells underwent immunoblot with the indicated antibodies. Numbers indicated densitometric quantiﬁcation of
the ratio phospho-p53/actin. Densitometric quantiﬁcation of phospho-p53/actin, normalized to untreated, for two independent
experiments is shown in the graph.
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protein by western blot (Supplementary Figures S4A
and C) and densitometric analysis (Supplementary Figures
S4B and D).
To determine whether DNA machinery was triggered
after treatment with melatonin and CDDP alone or in
combination, we performed immunoﬂuorescent staining
of gH2AX for up to 6 h after treatment. Melatonin and
CDDP alone, as well as in combination, induced
gH2AX foci formation within 1 h of treatment in both
MCF-7 (Supplementary Figure S4E) and HCT116
(Supplementary Figure S4F).
Melatonin-induced p53 phosphorylation is mediated
by p38 MAPK but not by ATM kinase
Given that ATM is known as the principal regulator of
p53 function upon DNA damage (Banin et al., 1998),
there was a need to study the role of ATM in melatonin-
induced p53 phosphorylation. To this purpose, we
treated ATM-deﬁcient and ATM-reconstituted cells
with melatonin and monitored p53 phosphorylation.
Interestingly, melatonin treatment induced p53 phos-
phorylation in both ATM-deﬁcient cells and ATM-
reconstituted cells (Figure 5a). Furthermore, to chemi-
cally inhibit ATM, we treated MCF-7 cells with caffeine
for 2 h and then added melatonin for 2 h. Caffeine did
not impair p53 phosphorylation after melatonin treat-
ment (Figure 5b and Supplementary Figure S6).
In addition, we performed comet assays in ATM-
deﬁcient cells and ATM-reconstituted cells. Melatonin
reduced DNA fragmentation even in the absence of
ATM (Figure 5c), thus providing further support to our
ﬁnding that ATM is not required for the activation
of p53 by melatonin. When the DNA repair machinery
is activated, ATM is phosphorylated in Ser-1881
(Shiloh, 2003). This prompted us to investigate whether
melatonin had any effect on ATM phosphorylation.
We performed immunoﬂuorescent staining of phos-
phorylated ATM in MCF-7 and HCT116 cells treated
with either melatonin or CDDP alone or in combina-
tion. CDDP alone induced phosphorylation of ATM,
whereas melatonin failed to do so (Supplementary
Figure S5). The combination of the two compounds
did not lead to any further increase in phosphorylated
ATM (Supplementary Figures S5A and B).
Evidence shows that p38 MAPK phosphorylates p53
at Ser-15 residue (She et al., 2000; Kim and Yoo, 2010).
To assess whether melatonin-induced p53 phosphoryla-
tion occurs through p38 kinase activity, we ﬁrst checked
p38 MAPK expression levels after adding melatonin.
We observed that melatonin promoted p38 MAPK
protein accumulation (Figure 6a). It is worth mention-
ing that the chemical inhibition of p38 MAPK activity
by using PD98059 (a MEK1 inhibitor) and SB202190 (a
p38a and p38b inhibitor) severely impaired melatonin-
induced p53 phosphorylation at Ser-15 in MCF-7 cells
(Figure 6b). Therefore, we hypothesized that p53-
mediated reduction of DNA fragmentation by melato-
nin could also be affected. To this purpose, we
performed comet assays in MCF-7 cells treated with
either ethanol or PD. PD impaired melatonin’s ability to
reduce DNA fragmentation caused by CDDP treatment
(Figure 6c).
Overall, these ﬁndings illustrate that to reduce DNA
damage accumulation by melatonin, efﬁcient phosphor-
ylation of p53 by p38 MAPK is required.
As H2AX can be phosphorylated through the p38
pathway upon DNA damage (Chiu et al., 2008), we also
tested whether chemical inhibition of p38 would result in
impaired phosphorylation of H2AX upon melatonin
treatment. Treatment with PD and SB inhibitors
impaired melatonin-induced H2AX phosphorylation
(Figure 6b), similar to the results observed for p53.
- + - Mel
NT Caffeine
P-p53 (Ser15)
GAPDH
0
10
20
30
40
50
60
70
80
90
100
-CDDP +CDDP
%
 c
om
et
s
-Mel
+Mel
-Mel
+Mel
ATM -/-
0
5
10
15
20
25
30
35
40
45
50
-CDDP +CDDP
%
 c
om
et
s
ATM +/+
P-p53 (Ser-15)
nucleolin
0’ 30’ 60’ 120’ 180’ 0’ 30’ 60’ 120’ 180’ Mel
ATM +/+ATM -/-
1 1.93 2.17 1.36 2.03 1 1.65 1.12 1.11 1.72
+
1 1.74 1 1.43
Figure 5 ATM is not required for melatonin-induced p53 activation. (a) ATM/ and ATM-reconstituted cells were treated with
melatonin for the indicated time; protein extracts were subjected to immunoblot with the indicated antibodies. Numbers indicated
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Discussion
There is widespread belief that ﬁnding novel therapeutic
and preventive approaches through basic research are
the key elements towards ﬁghting cancer successfully.
Epidemiological studies have shown that melatonin
decreases the risk of developing breast and other kinds
of cancer (Kliukiene et al., 2001; Kloog et al., 2008;
Schernhammer et al., 2008, 2009, 2009, 2010; Alpert
et al., 2009). However, very little is known about the
molecular mechanisms by which melatonin accom-
plishes its anticancer effects. This may occur through
downregulation of aberrant oncogenic activities or
activation of tumor-suppressor pathways. This paper
provides strong evidence how melatonin exerts its
oncostatic effects by activating the p53 tumor-suppres-
sor pathway. This correlates with previous observations
showing that melatonin induces p53 and p21 proteins,
leading to inhibition of cell proliferation (Mediavilla
et al., 1999). p53 is a master regulator that elicits
anticancer effects ranging from growth arrest and
apoptosis to senescence and DNA repair. These effects
are achieved by p53 through a combination of
transcriptional and post-translational events. p53 is a
transcription factor that regulates the expression of
a large cohort of target genes. Growing evidence
indicates that the transcriptional activity of p53 is
tightly regulated by a complex network of protein–
protein interactions. The outcome of this is either p53
accumulation or destabilization, resulting in potentiat-
ing or impairing its tumor-suppressor activities. Mela-
tonin treatment induces the accumulation of heavily
phosphorylated p53 protein (Kim and Yoo, 2010). This
occurs at a speciﬁc p53 residue (Ser-15) (Kim and Yoo,
2010) that has been shown to have a critical role in
orchestrating p53-reponse upon DNA-damaging agents
(Lakin and Jackson, 1999; Helton and Chen, 2007).
In response to DNA damage, different kinases, including
ATM and p38 MAPK, phosphorylate p53 at Ser-15
residue. We demonstrate that melatonin-induced p53
phosphorylation requires p38 MAPK activity (Figure 6),
but not ATM (Figure 5). It is crucial to mention that
melatonin treatment does not provoke any DNA damage
in both immortalized and transformed cells. Despite this,
melatonin induces the expression of the DNA damage-
sensing and repair proteins gH2AX and PML (Figures 4c
and d), which are known interactors of p53 (Carbone
et al., 2002). ATM and ATR phosphorylate H2AX when
double-strand breaks occur. However, in the absence of
double-strand breaks (that is, when single-strand breaks
occur instead) or in cells lacking ATM, other kinases can
phosphorylate H2AX (Kinner et al., 2008; Shrivastav
et al., 2008). p38 MAPK is one of those kinases (Chiu
et al., 2008). This actually happens in cells treated with
melatonin, in which gH2AX increases without ATM
phosphorylation, given the absence of double-strand
breaks (Supplementary Figures S4 and S5). Further
support is provided by the impairment of H2AX
phosphorylation by melatonin upon chemical inhibition
of p38 MAPK (Figure 6b). Owing to its radical scavenger
properties, melatonin can prevent DNA fragmentation
caused by free radical-generating chemicals, such as H2O2
(Sliwinski et al., 2007). Here, we show that melatonin
induces DNA repair proteins. This results in DNA
damage reduction after various types of DNA insults.
This effect is achieved by assembling a p53-mediated
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Figure 6 p38MAPK activity is required for melatonin-induced p53 phosphorylation. (a) MCF-7 cells were treated with melatonin for
the indicated time; protein extracts underwent immunoblot with the indicated antibodies. (b) MCF-7 cells were either pretreated or not
with 5 mM PD98059 or 5 mM SB202190 for 2 h and then either treated or not with 1mM melatonin for an additional 2 h; protein extracts
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DNA repair response that signiﬁcantly reduces the
accumulation of mutations (Figure 2b). In addition, we
demonstrated that p53 activation by melatonin does not
lead to apoptosis induction or p53-mediated senescence
(Supplementary Figure S1). Most importantly, this does
not pair with p53-mediated pro-survival effects, as
melatonin does not counteract apoptosis induced by
chemotherapy (Supplementary Figures S2 and S3A–D).
One study demonstrated that 1mM melatonin induces p53
phosphorylation at Ser-15 and apoptosis in androgen-
sensitive LNCaP prostate cancer cells (Kim and Yoo,
2010). The concentration of melatonin used in this study
is far higher than both physiological levels (1mM vs 1nM)
and levels reached when melatonin is used to treat sleep
disorders or as an adjuvant for anticancer therapy
(Vakkuri et al., 1985; Kane et al., 1994; Markantonis
et al., 2008), in which the highest concentration is 0.5mM.
A previous report by Xi et al. (2000) showed that
physiological concentrations of melatonin (for example,
0.5–5nM) are able to reduce cell proliferation in LNCaP
cells. A report from Sainz et al. (2005) showed that
melatonin (0.5–2mM for 6 days) induced marked G1 arrest
and S-phase reduction, but no change in cell viability was
observed. These data pair with our reported ﬁndings.
Owing to air, soil and water pollution, we are
continuously exposed to DNA insults. Under physiolo-
gical conditions, DNA insults determine DNA damage
that can be largely mended by the cell’s DNA repair
machinery. Inevitably, a number of errors occurring in
the DNA will not be repaired efﬁciently and cells will
accumulate mutations. On the other hand, in the event
of a DNA insult occurring, particularly when a certain
amount of proteins is involved in the DNA repair, the
cell is ready to repair DNA lesions and thus a lower
number of mutations are consequently generated. It is
reasonable to speculate that melatonin anticancer activity
may have a role in safeguarding DNA from insults that
might otherwise cause genetic alterations. This occurs, at
least in part, through a speciﬁc cascade of events including
p38-mediated phosphorylation, activation of p53 and
consequently the induction of DNA repair proteins
(Figure 7). An increase in the DNA repair machinery by
melatonin might: (1) prevent carcinogenesis in healthy
subjects, making it suitable to use in primary chemopre-
vention; (2) prevent accumulation of additional mutations
in pre-cancerous lesions, thereby preventing carcinogenesis
in high-risk patients and therefore be used in secondary
chemoprevention; (3) prevent mutations in cancer cells,
reducing the risk of developing a more aggressive
phenotype (for example, invasiveness and metastatization)
and consequently avoid giving the worst prognosis to
cancer patients (tertiary chemoprevention); (4) limit the
bystander effects induced by anticancer therapy in healthy
tissues, thus maintaining genome stability and preventing
the formation of second malignant neoplasms. In order for
this to be possible, further study is required on the
molecular chemoprevention targets triggered by melatonin.
Materials and methods
Cell culture and transfection
HCT116, MCF-7, mouse embryo ﬁbroblast, ATM/ and
ATM þ /þ cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium supplemented with 10% fetal calf serum, 2mM
L-glutamine, 100Units/ml penicillin and 100mg/ml streptomy-
cin (Gibco, Carlsbad, CA, USA). In addition, ATM/ and
ATMþ /þ cells were cultured in the presence of 100 mg/ml
hygromicin B (Sigma, St Louis, MO, USA). MCF-10A cells
were cultured in Dulbecco’s modiﬁed Eagle’s medium F-12
with Glutamax, which is supplemented with 5% horse serum
(Invitrogen), 0.5 mg/ml hydrocortisone, 20 ng/ml epidermal
growth factor (EGF), 10 mg/ml insulin, 2mM L-glutamine,
100Units/ml penicillin and 100mg/ml streptomycin. All cell
lines were grown at 37 1C in 5% CO2. Transfections were
performed with Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s recommendations.
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Figure 7 Model depicting melatonin’s action. Melatonin treatment induces a p38-dependent phosphorylation cascade that activates
p53 and other repair proteins. This translates in an increased ability of cells to detect DNA damage and repair it. This results in a lower
mutation frequency.
Melatonin prevents DNA damage through p53 phosphorylation
R Santoro et al
2939
Oncogene
MCF-7 stable cell lines were obtained as follows: cells were
transfected with pRS-sh-LacZ and pRS-sh-p53 and resistant
cells were selected by treatment with 1mg/ml Puromycin
(P8833, Sigma) for 5 days.
Reagents
Melatonin (M5250), caffeine (C0750), PD98059 (P215),
SB202190 (S7067) were purchased from Sigma-Aldrich
(St Louis, MO, USA).
Growth curves and colony-forming assays
For growth curves, 7103 cells/well were seeded in 24-well dishes.
Cells were harvested at the indicated times by trypsin detachment
and counted either manually (Figure 1 and Supplementary Figure
S1A) or automatically using a Guava EasyCyte 8HT ﬂow
cytometer (Millipore, Billerica, MA, USA). In the latter case, cell
concentration (cells/ml) is shown on the Y axis.
With regard to colony-forming assays, 5102 cells
were seeded in 35-mm dishes and grown for 15 days. Cells
were stained with crystal violet and colonies counted.
To maintain melatonin levels (Roy et al., 2001), the medium
was changed every 48 h in both experiments.
Western blots
Total protein extracts were prepared by lysing cells in 8M urea.
For nuclear extract preparation, cells were lysed in hypotonic
buffer (10mM Hepes, pH 8.0, 10mM KCl, 1.5mMMgCl2, 0.1mM
EGTA, 0.5mM DTT, 0.5mM phenylmethylsulfonyl ﬂuoride
(PMSF), 0.1mM sodium orthovanadate, 10mM b-glyceropho-
sphate and protease inhibitors), nuclei were pelleted at 500 rcf for
10min and lysed in nuclei lysis buffer (50mM Tris–Cl, pH 8.0,
10mM EDTA, 1% SDS and protease inhibitors). Acid extracts
(for total H2AX staining): cells were lysed in 1 volume TEN
buffer (0.5% Triton in phosphate-buffered saline (PBS)) on ice
for 10min, centrifuged at 500 rcf for 10min at 4 1C and washed
once more with TEN buffer; nuclei were then lysed overnight at
4 1C in a half volume of 0.2 N HCl; lysates were buffered with 1/
10 volume of 100mM Tris, pH 8.0.
All protein extracts were quantiﬁed by Bradford assay and
equal amounts were loaded onto SDS–PAGE, transferred to
polyvinylidene ﬂuoride membranes (Immobilon-P, Millipore)
and underwent immunoblot with the indicated antibodies.
Antibodies to p53 (sc-125, DO-1, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), phospho-p53 Ser-15 (9284, Cell
Signaling, Danvers, MA, USA), b-actin (A2288, AC-74, Sigma),
p21 (2947, Cell Signaling), nucleolin (ab13541, 4E2, Abcam,
Cambridge, UK), gH2AX (9718, 20E3, Cell Signaling), p38
(9212, Cell Signaling) and PML (sc-5621, H-238, Santa Cruz
Biotechnology) were diluted in 5% bovine serum albumin/Tris-
buffered salines/0.1% Tween-20. Secondary anti-mouse and
anti-rabbit antibodies were purchased from Bio-Rad (Hercules,
CA, USA). Images were acquired using a VersaDoc MP
instrument (Bio-Rad). Signal intensity was quantiﬁed using the
Quantity One software (Bio-Rad) where indicated.
Immunoﬂuorescence
In all, 2.5104. cells were plated in a 8-well chamber slide
(177402, Lab-Tek, Nunc, Roskilde, DK) and treated as
indicated. Cells were ﬁxed for 20min with 4% paraformaldehyde
in PBS and permeabilized for 25min with 0.2% Triton X-100 in
PBS. Cells were then incubated with the indicated primary
antibodies for 1h and subsequently with goat anti-rabbit Alexa
Fluor 488 (A11034, Invitrogen) and goat anti-mouse Alexa
Fluor 594 (A11032, Invitrogen). Nuclei were stained with DAPI
(40,6-diamidino-2-phenylindole). Pictures were taken using  63
magniﬁcation on an Axiovert 200M microscope and Axiovision
acquisition program (Zeiss, Thornwood, NY, USA).
RAPD analysis
In all, 100 ng of genomic DNA was ampliﬁed by PCR as
described previously (Xian et al., 2005) with the following primers:
#1: 50-CCGGCTACGG-30; #2: 50-CAGGCCCTTC-30; #3: 50-AA
CGGTCACG-30; #4: 50-AGCTGCCGGG-30; #5: 50-AGGCA
TTCCC-30; #6: 50-GGTCTGAACC; #7: 50-AAGGCTAACG-30.
PCR products were run onto a 2% agarose gel (Bio-Rad),
stained with ethidium bromide (Sigma) and images were
acquired using a VersaDoc MP instrument (Bio-Rad).
Comet assays
After treatment, cells were detached with trypsin and
embedded in 1% low melting agarose (Sigma) in PBS and
spread onto microscopy slides previously coated with 1%
Agarose (Bio-Rad). Cells were lysed in the lysis solution (2.5M
NaCl, 100mM EDTA, 10mM Tris base, 8 g/l NaOH, 1%
Triton X-100, 10% dimethyl sulfoxide) for 1 h at room
temperature and then run in running solution (300mM NaOH,
1mM EDTA, pH 13.0) for 30min at 25V and 250mA. DNA
was equilibrated with 0.4M Tris pH 8.0 and slides were dried
with methanol. DNA was stained with propidium iodide
(Sigma) and pictures were taken using  20 magniﬁcation on
an Axiovert 200M microscope and Axiovision acquisition
program (Zeiss). At least 300 cells were scored for each slide.
Cell-cycle distribution
Cells were treated with melatonin for the indicated time and
processed as described in the study by Ji et al. (2010). Samples
were acquired using a Guava EasyCyte 8HT ﬂow cytometer
(Millipore). Cell-cycle distribution is shown.
BrdU incorporation
Cells were treated as indicated in the ﬁgures legend, labeled with
10mM BrdU (5-bromo-20-deoxyuridine) for 40min. Cells were
then detached with trypsin and stained using the ‘5-Bromo-20-
deoxy-uridine labeling and detection kit I’ (11296736001, Roche,
Basel, Switzerland) following the manufacturer’s guidelines.
Samples were acquired using a Guava EasyCyte 8HT ﬂow
cytometer (Millipore). Cell-cycle distribution is shown.
Annexin V staining
Cells were treated as indicated in the ﬁgures legend. Cells were
detached with trypsin and stained using the ‘Vybrant
Apoptosis Assay Kit #2’ (V13241, Invitrogen) following the
manufacturer’s recommendations. Samples were acquired
using a Guava EasyCyte 8HT ﬂow cytometer (Millipore).
Percentage of Annexin V positive cells is shown.
Senescence-associated b-galactoside staining
Cells were treated as indicated in the ﬁgures legend. Cells were
ﬁxed with 3% paraformaldehyde for 5min at room tempera-
ture, washed with PBS and stained overnight at 37 1C
with senescence-associated b-galactoside staining solution
(5mM potassium ferrocyanide, 5mM potassium ferricyanide,
2mM MgCl2, 1mg/ml X-gal, pH 6.0).
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